Chief Executive Officer/Founder Neurogen Biomarking
Joined November 2011
- Tweets 290
- Following 599
- Followers 651
- Likes 550
46 Photos and videos
12 Nov 2025
62
2 Sep 2025
How Neurogen Biomarking Is Ushering In A New Era Of Brain Health maxim.com/partner/how-neurog…
2
88
22 Aug 2025
Neurogen Biomarking: The Company That’s Changing the Future of Brain Health usatoday.com/story/special/c… via @usatoday
1
173
20 Feb 2025
Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer’s Disease finance.yahoo.com/news/neuro…
2
178
Dr. Rany Aburashed retweeted
23 Aug 2021
Join here tomorrow for the launch of a new accredited #tweetorial on "Insights into #MultipleSclerosis disease course through the Topographical Model of #MS"! Earn 0.5 CE/CME credits: #physicians, #nurses, #pharmacists! Expert faculty is @SKriegerMD.
1
5
19
Dr. Rany Aburashed retweeted
4 Aug 2021
36) That's it! You made it! Free CE/#CME! Now go to academiccme.com/MSdiagnosis and claim your credit! I am @RanyAburashed. Follow @MS_CME for more tweetorials, and visit us at academiccme.com/MSswitching and . . .
1
2
3
Dr. Rany Aburashed retweeted
4 Aug 2021
35) suboptimal treatment response, and hopefully serve as predictive models where early intervention can change the natural history of disease on an individual level.
1
2
2
Dr. Rany Aburashed retweeted
4 Aug 2021
34) Summary: MS prognosis remains difficult to predict on an individual basis! Emerging individual serum biomarkers or a collection of bioprofiles may help in earlier detection of disease progression,
1
2
1
Dr. Rany Aburashed retweeted
4 Aug 2021
33) CHIL31 levels at baseline also have been found to correlate with disability progression in patients with MS. Multiple Sclerosis 2015;21(14): 1761-1770. Brain 2010;133:1092-1093
1
1
Dr. Rany Aburashed retweeted
4 Aug 2021
32) Chitinase 3-Like 1 or CHI3L1 is a glycoprotein expressed in activated glia, activated macrophages, and vascular smooth muscle. It is overexpressed in patients with CIS who convert to cdMS and is also correlated with GAD enhancing lesions on MRI.
1
1
Dr. Rany Aburashed retweeted
4 Aug 2021
31) Elevated GFAP levels have been shown to be associated with disability severity and ambulatory loss in patients with MS. Brain 2002; 125(Pt. 7): 1462–1473.
1
1
Dr. Rany Aburashed retweeted
4 Aug 2021
30) GFAP is another important potential marker for disease monitoring/prognostication. It is an astrocytic cytoskeletal protein that is highly expressed in astrogliosis in MS lesions.
1
1
1
Dr. Rany Aburashed retweeted
4 Aug 2021
29) The answer is (a), clinical relapse or disease activity.
1
1
Dr. Rany Aburashed retweeted
4 Aug 2021
28) Elevated neurofilament light levels most likely represent which of the following?
a. Clinical relapse or disease activity
b. MS subtype
c. Cognitive decline
d. DMT optimal response
67%
a
17%
b
17%
c
0%
d
6 votes • Final results
2
1
2
Dr. Rany Aburashed retweeted
4 Aug 2021
27) . . . making this a promising prospect to monitor disease activity as well as treatment response during routine clinical care. J Neurol Neurosurg Psych 2016;87:126. Serum NfL levels are particularly high in pwMS with gadolinium enhancing MRI lesions. Ann Neurol 2017;81:857
1
1
1
Dr. Rany Aburashed retweeted
4 Aug 2021
26) Recent advances in ELISA assays using Single Molecule Array Assays (SIMOA) have led to the potential utility of measuring Neurofilaments in biofluid with high correlation to CSF . . .
1
1
1
Dr. Rany Aburashed retweeted
4 Aug 2021
25) Neurofilaments form the cytoskeleton of myelinated axons and may increase surface area of axons, provide stability, as well as assist with electrical transmission within neurons. J. Cell Sci. 125, 3257–3263
1
1
2
Dr. Rany Aburashed retweeted
4 Aug 2021
24) Neurofilament Light may serve as a nonspecific but quantitative marker of axonal and neuronal injury in patients with multiple sclerosis (doi.org/10.1038/s41598-020-6…).
1
2
2